Search filters

List of works by Gianantonio Rosti

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia

scientific article published on 6 July 2015

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

scientific article

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

scientific article published in March 2002

A review of the European LeukemiaNet recommendations for the management of CML.

scientific article published on 27 March 2015

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

article by Simona Soverini et al published 20 June 2005 in Journal of Clinical Oncology

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

scientific article

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

scientific article

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis

scientific article published on August 2012

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

scientific article published on 11 May 2011

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

scientific article published on 14 August 2014

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

scientific article

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia

scientific article

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

scientific article published on 31 May 2011

Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications

scientific article published in June 2010

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

scientific article published on 06 October 2008

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.

scientific article

Chronic myeloid leukemia: room for improvement?

scientific article published on July 2017

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

scientific article published in January 2006

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

scientific article

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

scientific article

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

scientific article published on 17 December 2013

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

scientific article published on April 2010

Dasatinib first-line: Multicentric Italian experience outside clinical trials

scientific article

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

scientific article

Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

scientific article published on 25 March 2014

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet

scientific article published on 16 April 2012

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

scientific article published on 3 May 2010

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

scientific article published on 23 April 2004

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells

scientific article published on 8 May 2017

Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia

scientific article published on May 2012

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

scientific article

Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.

scientific article

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

scientific article

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

scientific article

Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.

scientific article

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

scientific article published on 26 June 2013

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

scientific article

Explaining the in vitro and in vivo differences in leukemia therapy.

scientific article published on 15 May 2011

FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage

scientific article published on 12 April 2017

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation ⬇️

scientific article published on November 29, 2012

First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies

scientific article published on April 2014

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

scientific article published on 26 March 2008

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

scientific article published on September 2016

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

scientific article

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib

scientific article published on 2 March 2018

Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion

scientific article

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

scientific article

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

scientific article published on 27 August 2016

Imatinib in chronic myeloid leukemia elderly patients ⬇️

scientific article published on December 1, 2011

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

scientific article published in February 2004

Imatinib mesylate in the treatment of hematologic malignancies

scientific article published on October 2007

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

scientific article published on 10 October 2012

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

scientific article

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors

scientific article published on 02 October 2013

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

scientific article

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

scientific article

Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristics ⬇️

scientific article published on October 11, 2010

Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results

scientific article published in January 2009

Interferon-alfa for chronic myeloid leukemia

scientific article

International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.

scientific article

Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.

scientific article

Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia

scientific article published on 21 July 2015

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

scientific article published on 25 June 2015

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

scientific article published in January 2008

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

scientific article

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

scientific article

Molecular monitoring

scientific article published on March 2014

Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia

scientific article published on 17 January 2013

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

scientific article

Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden

scientific article published on February 2014

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

scientific article published on 9 March 2016

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

scientific article published on 28 July 2016

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

scientific article

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

scientific article published on 12 October 2009

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

scientific article published on 15 March 2013

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

scientific article published on 17 August 2011

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

scientific article published on June 2007

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

scientific article published on 16 July 2012

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

scientific article published on 16 July 2009

Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia

scientific article

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

scientific article published on 9 July 2009

Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.

scientific article published on 12 August 2011

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients

scientific article published on 18 October 2017

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

scientific article published on 2 October 2017

Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel

scientific article published on 8 October 2017

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

scientific article

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

scientific article published on 2 May 2011

Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors

scientific article published on 30 July 2013

Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies

scientific article published on 23 July 2016

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

scientific article published on 30 May 2018

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

scientific article published on 11 February 2009

Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia

scientific article published in March 2003

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

scientific article published on 11 March 2016

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

scientific article published on 14 February 2014

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase

scientific article published on 11 May 2011

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

scientific article published on 29 May 2009

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

article by Simona Soverini et al published March 2007 in Lancet Oncology Commission

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

scientific article published on 2 May 2017

The cytogenetic response as a surrogate marker of survival

scientific article

The effects of imatinib on pregnancy outcome

scientific article published on 05 March 2008

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

scientific article published on 14 January 2009

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

scientific article

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

scientific article published in February 2009

Treatment recommendations for chronic myeloid leukemia

scientific article published on 02 January 2014

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

scientific article

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

scientific article

Paulina is supported by:

About Paulina

Help